What Is The Role That Glutamate Plays In Mood Disorders & Schizophrenia?
View the full webinar on PsychU: https://bit.ly/3dAbExn Glutamate is the predominant excitatory neurotransmitter in the nervous system, and glutamatergic dysregulation has been implicated in the pathophysiology of both mood disorders and schizophrenia. In this video Dr. James Murrough and Dr. Laura Rowland provide an overview of glutamate, including a discussion of glutamate receptors and synapse; measurement via proton magnetic resonance spectroscopy; and the current understanding behind the role glutamate may play in these mental illnesses. #Glutamate #Schizophrenia #MoodDisorders #MentalHealth James W. Murrough, MD, PhD, is an Associate Professor of Psychiatry & Neuroscience, as well as the Director of the Depression & Anxiety Center for Discovery & Treatment at the Icahn School of Medicine at Mount Sinai. Laura M. Rowland, PhD, is an Associate Professor in the Maryland Psychiatric Research Center (MPRC), Department of Psychiatry at the University of Maryland School of Medicine; the Director of the Chemical Imaging Core, housed within the Neuroimaging Research Program at MPRC; and the Co-Director of the MPRC postdoctoral training program. Speakers were paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as nor is it a substitute for medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available throught any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC. View the full webinar on PsychU: https://bit.ly/3dAbExn MRC2.CORP.X.03361

The Role of Glutamatergic Signaling in Major Depressive Disorder

Causes of Schizophrenia. Glutamate and the Glutamate Hypothesis

Treating Prolonged Grief Disorder: A Post-Loss Stress Disorder

Revisiting Cognitive Deficits In Bipolar Disorder

Schizophrenia Showdown: Dopamine or Glutamate? Shocking Neuroscience!

The New Science of Ketamine For Depression (with James Murrough, MD, PhD)

A tale of mental illness | Elyn Saks

Brain Plasticity: The Effects of Antidepressants on Major Depression

Schizophrenia: Neurotransmitter Tracts, Causes, Treatment & Assessment – Psychiatry | Lecturio

The Neurobiology of Prefrontal Cortex and its Role in Mental Disorders

Episode 163: Mark Mattson discusses glutamate, the brain’s most important neurotransmitter

What is Schizophrenia? - It's More Than Hallucinations

Understanding & Conquering Depression | Huberman Lab Essentials

Updates on Progressive Supranuclear Palsy(PSP) & Corticobasal Degeneration(CBD): Tale of Two Cousins

Dopamine Pathways, Antipsychotics, and EPS

Rapid-Acting Antidepressants: New Treatments, New Hope, and New Insights: Dr. John Krystal

Glutamate in Schizophrenia: Treatment, Target or Biomarker? | BRAINCAST with Dr. Pospo

Antipsychotics Mnemonics (Memorable Psychopharmacology Lecture 4)

Somatoform Disorders (Somatic Symptom, Conversion, Illness Anxiety, Factitious, Malingering)

